Excellent sector fit: explicit TechBio focus with pharma partnership pipeline aligns perfectly with venture's drug resistance prediction tool. Pre-seed stage match. Minor geographic offset: Switzerland vs France/Île-de-France primary target, though Basel is EU-adjacent and within plausible expansion geography.
2026-07-09OPEN → INELIGIBLE· Application window closed May 31, 2026; today is July 9, 2026. Selection Days (June 25–26, 2026) have already occurred and the 2026 cohort has been selected.